LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/CE Mark for TyPEEK
Company News

CE Mark for TyPEEK

September 17, 2013 1 min read Premium comments

Advertisement

CE Mark for TyPEEK
TyPEEK Interbody Spacer / Courtesy: Tyber Medical, LLC
Secondary

Morristown, New Jersey-based Tyber Medical, LLC has been granted CE Mark for its TyPEEK, proprietary titanium plasma sprayed PEEK interbody system.

According to the company’s September 10, 2013 announcement, the interbody fusion device is designed to offer the benefits of bone growth with titanium along with the modulus and the post-op imaging characteristic of PEEK for situation where PEEK alone may not provide the best setting for fusion.

Mark Schenk, director of regulatory affairs and quality assurance for the company said, “Receiving ISO 13485 certification and CE Mark approval within our first year demonstrates the ability of our quality system and our team to efficiently design, develop and gain regulatory approval for products that have leading edge technology, while ensuring that they are safe and effective.”

The company says its build to order operation accelerates a sales force access to products without incurring substantial development expenses or timeline risks. Their competitive pricing targets a 75% margin or savings on all implants. All of the company’s released products have FDA and CE regulatory clearance. The systems are fully designed, tested, verified and validated using Tyber Medical’s ISO 13485:2003 and FDA QSR compliant quality system.

Steve Zeiger, the company’s director of sales and marketing told OTW, “Once a company decides they must begin to offer a product, our private label model offers the opportunity to jump past the capital expenditure and avoid the regulatory risks of internal development. Once in the market, our model reduces cogs through consolidation of manufacturing.”

The company’s interbody fusion devices include configurations for anterior cervical (ACIF), anterior lumbar (ALIF), posterior lumbar (PLIF), oblique lumbar (OLIF), transforaminal lumbar (TLIF), and direct lateral (DLIF) interbody spacers.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy